• Sun. Oct 17th, 2021

AstraZeneca news Italy: study on thrombosis and open day: the news

Byeditorial

May 20, 2021

AstraZeneca, the latest news from Italy on the vaccine with a study on the connection between anti Covid products and rare thrombosis between side effects and the new open day in the Lazio Region. In fact, on Saturday 22nd and Sunday 23rd, the weekend dedicated to vaccination with AstraZeneca in Lazio returns for those born from 1981 and previous years. “We repeat a lucky formula that has been very successful and that goes to increase the vaccination campaign in Lazio which is proceeding quickly”, underlines in a note the councilor for Health of the Lazio Region, Alessio D’Amato, who continues: “Citizens and citizens born from 1981 and previous years they can request the virtual ticket on the dedicated Ufirst app to fix the first dose of the AstraZeneca vaccine, being able to choose the time and hub. The vaccinations will be held until 24 hours, just bring the Health Card and the virtual ticket with you ” , concludes the commissioner. For all information relating to the points of administration, times and availability of doses: www.salutelazio.it/open-day-con-ticket-virtuale. To collect the virtual ticket subject to availability: www.ufirst.page.link/open-day-regione-lazio, or download the UFirst app for free. Meanwhile, the first clinical study in Italy that investigates the connection between vaccination leaves in Milan anti-Covid and thrombotic events “. It was led by the Monzino Cardiology Center (Ccm) and the State University of the Lombard capital, who announce the launch of the ‘Treasure’ project with the aim of “evaluating any variation in platelet activation, the mechanism at the origin thrombosis, induced by the administration of both mRna vaccines such as Pfizer and Moderna, and viral vector vaccines such as AstraZeneca and Johnson & Johnson “. Monzino and UniMi are looking for 200 Milanese interested in participating in the research, undergoing a simple blood test before and after vaccination. “Participate in the study” is the appeal launched by the IRCCS of the heart and by the university in via Festa del Perdono. “In addition to contributing to the collective knowledge on anti-Covid vaccines – they underline – the participants will enter a program to control their cardiovascular situation, which it is always good to monitor, especially in this pandemic period”. characterize the state of platelet activation before vaccination and evaluate any post-vaccine variation, also highlighting whether different types of shield product determine a different platelet activation. Treasure is aimed at the population aged 18 to 79, who must receive the first or second dose of Sars-Cov-2 vaccine. “The cases of thrombosis, although rare, following the administration of the AstraZeneca vaccine, have sown panic. But in reality there is no scientific proof of a causal link, nor that women are more at risk – says Marina Camera, professor at the University of Milan and head of the Cardiovascular Cell and Molecular Biology Unit Ccm – For this reason, international scientific societies have recommended investigating the mechanisms of interaction between blood cells and vaccines. An invitation that we immediately accepted. The anti-Covid vaccination campaign will not end in 2021, but will accompany us for several years as central theme of public health “, underlines the expert, highlighting the importance of experimentation. “According to the recommendations issued by the European health authorities after an initial examination of the available data – remembers Camera – the most suspected are viral vector vaccines, so much so that in Italy they are reserved” preferentially “for the over 60s, age in which the thrombotic events did not occur. The doubt remains that the reported cases, very few, compared to the millions of doses already administered in England and the United States – the teacher points out – have nothing to do with the vaccine. , their number is practically identical to the thrombosis affecting the unvaccinated population. For this reason it is absolutely necessary to know more “. And it is essential “not to suspend or slow down the vaccination campaign: getting sick with Covid-19 – warns Camera – is much more dangerous than getting a vaccine. I therefore appeal to the Milanese to participate in our study and help research”.

One thought on “AstraZeneca news Italy: study on thrombosis and open day: the news”
  1. editorial says:

    https://connect.informs.org/network/members/profile?UserKey=8dd1efb3-b021-4ce7-9609-7a12f6fc7745
    https://connect.informs.org/network/members/profile?UserKey=2b79ee2a-e7ae-4b68-a4d2-076b58748cf5
    https://connect.informs.org/network/members/profile?UserKey=ee1ef6d6-046c-4957-83fc-325e4b653f8a
    https://connect.informs.org/network/members/profile?UserKey=fa3ddac8-9186-4293-b6a3-498e2ec2f6ea
    https://connect.informs.org/network/members/profile?UserKey=b742dee3-77ff-4c6b-8204-b0ca7d79ae69
    https://connect.informs.org/network/members/profile?UserKey=93b80a81-5cf5-4671-bd1e-91b78f1eff3d
    https://connect.informs.org/network/members/profile?UserKey=ab5279b6-f8e3-4174-b712-f03a6d9cde45
    https://connect.informs.org/network/members/profile?UserKey=f3d37b51-8d73-49e0-a49c-b211f3551c09
    https://connect.informs.org/network/members/profile?UserKey=c9089bf5-ac70-4966-ba5b-e6f6a8d37dc6
    https://connect.informs.org/network/members/profile?UserKey=08f52865-aa26-4573-8ef1-abd43e5706c7
    https://connect.informs.org/network/members/profile?UserKey=9ee0ee81-6879-4fea-8e9a-5df5fe567b3b
    https://connect.informs.org/network/members/profile?UserKey=8f731aeb-38f5-4810-ab56-7b5f1f349b9a
    https://connect.informs.org/network/members/profile?UserKey=e218ca2d-f1a3-4c0f-b737-8065065da0f0
    https://connect.informs.org/network/members/profile?UserKey=ccd8878a-e7f2-46d6-bc64-a59b5f525892
    https://connect.informs.org/network/members/profile?UserKey=40a91839-e9f6-458b-a1d9-807e4fc4a74c
    https://connect.informs.org/network/members/profile?UserKey=53f4d199-d63e-4f3c-81c4-4d9046e13eb2
    https://connect.informs.org/network/members/profile?UserKey=9c254409-1ff7-459a-9c1b-d07a5b407ccd
    https://connect.informs.org/network/members/profile?UserKey=e78923d6-8352-4300-bf64-edc59841ade2
    https://connect.informs.org/network/members/profile?UserKey=2b671d90-397e-4c52-8d68-b3c812772d7e
    https://connect.informs.org/network/members/profile?UserKey=c243a0b3-e2d0-420d-98c9-da9ed20760a3
    https://connect.informs.org/network/members/profile?UserKey=427567ae-50a3-4937-8077-1ed67a26d139
    https://connect.informs.org/network/members/profile?UserKey=33144e48-af0f-43b1-9a5f-f0ecbcd23a9f
    https://connect.informs.org/network/members/profile?UserKey=3d9b1bfb-6369-4aaf-9b5f-16b22bf9cb77
    https://connect.informs.org/network/members/profile?UserKey=df79608b-f786-4497-9d06-8e4796a9fd3a
    https://connect.informs.org/network/members/profile?UserKey=10b011a1-a307-4b3a-b395-451e056511ef
    https://connect.informs.org/network/members/profile?UserKey=53bdb76a-5a65-4220-a247-e39c1a8b1346
    https://connect.informs.org/network/members/profile?UserKey=b548291e-dd6a-46cd-ad6c-d2bec6f42f6d
    https://connect.informs.org/network/members/profile?UserKey=2c596bb7-48af-418b-b1b9-f53263a73c88
    https://connect.informs.org/network/members/profile?UserKey=355483f1-8599-4cc6-a74c-46930a5a0f97
    https://connect.informs.org/network/members/profile?UserKey=2a85d54f-707c-4efe-9adb-2659b21491ef
    https://connect.informs.org/network/members/profile?UserKey=3e1fac55-ff12-4b28-b041-8a023347bc20
    https://connect.informs.org/network/members/profile?UserKey=b43eac6b-2286-4fde-8fb5-fb4183bfdd45
    https://connect.informs.org/network/members/profile?UserKey=fe11fe20-9d0d-44f8-a9ab-604fc3b60d1b
    https://connect.informs.org/network/members/profile?UserKey=66f506d0-0a07-4fae-9e87-a103eb22f2ab
    https://connect.informs.org/network/members/profile?UserKey=11a5c79c-f562-4dad-9ece-585a720faf69
    https://connect.informs.org/network/members/profile?UserKey=4bbab6f1-ee2c-46a3-a0fa-8f96fb37e833
    https://connect.informs.org/network/members/profile?UserKey=12aac8c5-53bd-4273-b458-00ecc9747697
    https://connect.informs.org/network/members/profile?UserKey=da74f11f-b857-47a8-b0ec-9338f417347f
    https://connect.informs.org/network/members/profile?UserKey=a7765cd0-8046-42c8-bdc8-7bfda10296f9
    https://connect.informs.org/network/members/profile?UserKey=11172034-426a-439b-afff-52aa1ebd73d9
    https://connect.informs.org/network/members/profile?UserKey=093325e0-d965-4d5d-8edb-3e01cf5a03a2
    https://connect.informs.org/network/members/profile?UserKey=b1934dd8-bc86-49e8-bb5e-ccedaacce1f8
    https://connect.informs.org/network/members/profile?UserKey=096b0e1e-eef3-41c5-b4c4-e3b5684fa41f
    https://connect.informs.org/network/members/profile?UserKey=86e38785-a23e-4b17-bf7d-639e9e9cfcf5
    https://connect.informs.org/network/members/profile?UserKey=6fe15854-13a0-455b-bb71-f82ed3264f95
    https://connect.informs.org/network/members/profile?UserKey=44c4c2a6-8503-48a4-b207-687d2a68a72d
    https://connect.informs.org/network/members/profile?UserKey=d73cb2d0-3e14-4fb1-84fd-f66a989686b5
    https://connect.informs.org/network/members/profile?UserKey=b24d156f-f271-43a5-b10a-1d8ebac4426c
    https://connect.informs.org/network/members/profile?UserKey=600a62ce-d01a-42e9-946a-e6f93f633b5d
    https://connect.informs.org/network/members/profile?UserKey=6335257f-2169-485e-b844-e1b7531c6a79

Comments are closed.